Background: The safety and efficacy of the AbsorbÔ (Abbott) bioresorbable vascular scaffold (BVS) has been documented in lower-risk patient and lesion subsets with "real-world" outcome data being scarce. Here we report the experience gathered with BVS primarily in daily practice at a high-volume Dutch center. Methods: Between July 2009 -April 2014, a total of 169 patients (194 lesions) were treated with BVS, of which the first 36 patients were treated within the scope of the ABSORB studies. Clinical presentation of pts. (75% male, mean age 58 yrs, 16% diabetes) was ACS in 47%. Multi-vessel disease was present in 39%. Lesion complexity was B2/C in 59% and mean lesion length 18.2 mm. Pre-dilatation was performed in 96% and post-dilatation in 54%. The mean scaffold length was 29 mm with 34% of cases using !2 scaffolds and 25% of cases using overlapping or adjacent scaffolds. OCT or IVUS was used in 42%. Registry data was collected prospectively in-hospital, at 1 and 6 months and then yearly up to 4 years. Mean follow-up time was 298 days (range 0-1534 days) with 46% of patients having at least 1 year of follow-up. Results: Procedural success was 99.4% (failure to achieve stent-expansion in 1 pt.) and device success 98.8% (failure to deliver BVS in 2 pts.). Over the entire follow-up period, death occurred in 2.4% (2 cardiac and 2 non-cardiac), myocardial infarction (MI) in 3.0% (total of 5 cases, 1 of peri-procedural), target lesion revascularization in 3.6 %, target vessel revascularization (TVR) in 4.2%, non-target vessel revascularization 0.6%. Definite stent thrombosis (ST) occurred in 3 pts. (1.8%) and probable ST in 1 pt. (0.6%); all ST were early within 48 hours except one case of definite ST which occurred at 7 months. Overall MACE (death, MI, TVR) during follow-up occurred in 8.3% of patients (n¼14). Conclusions: This registry including patients with ACS and complex lesion characteristics documents a good efficacy and reasonable safety profile of the BVS. Stent thrombosis, in particular early after BVS implantation, is not infrequent and has to be closely monitored. Randomized data is needed to define the role of BVS in daily practice including complex patient and lesion subsets.
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Background: Bioresorbable vascular scaffolds (BVS, Abbott Vascular, Santa Clara, California, USA) are new options for treatment of coronary stenoses. Due to a large crossing profile, the implantation procedure is more complex than for current metal stents. Thus, a learning curve might be present. We analyzed whether there is a relationship between the outcome of coronary PCI with BVS and specific operator experience with this treatment modality. Methods: 200 consecutive patients included in a multi-center all-comers registry of coronary revascularization procedures with BVS were divided into the first 100 (group A) vs. the second 100 individuals (group B). We compared procedural parameters and complication rates, as well as in-hospital outcome and mid-term follow-up results.
Results: Baseline characteristics in both groups were not significantly different. Thoraxcenter, Rotterdam, MD Background: Although bioresorbable scaffolds (BRS) may have important benefits, their deployment requires more aggressive lesion preparation compared to the best metallic DES due to different radial force and crossing profile. In addition, the benefits of post dilatation (PD) have not been systematically studied, with reports of fracture if the BRS expansion limits are exceeded by excessive PD. We sought to determine the impact of PD on clinical outcomes in a large cohort of patients treated with the Absorb only. Methods: We evaluated all consecutive patients enrolled in the multicenter, single arm ABSORB EXTEND Study through June 2013. The study allowed treatment of up to 2 coronaries (diameter 2.0 to 3.8mm) and the use of overlapping (lesion length 28mm). Patients with severe lesion calcification/tortuosity were excluded. Aggressive lesion pre dilatation (balloon to artery ratio of 0.9-1.0) was mandatory and PD was left to the operator's discretion (if performed, non-compliant balloons up to 0.5mm larger than the Absorb had to be used). Patients were grouped according to whether PD was performed or not, and the one-year incidence of TLF and scaffold thrombosis were compared. Results: 768 patients were enrolled in the study and PD was performed in 526 (68.4%). There were no significant differences between the PD group and no-PD group in baseline characteristics, moderate calcification (13.7% vs.12.7%, p¼0.7) and incidence of B2/C lesions (43.9% vs. 41.8%), as well as lesion length (12.3mm vs. 12.1mm, p¼0.6) and RVD (2.6mm for both groups, p¼0.2). Residual in-scaffold stenosis (15.4 AE 6.5% with PD, 14.9 AE 6.1 without PD, p¼0.3) and the need for bailout scaffold/stent (4.2% with PD, 4.5% without PD, p¼0.8) were also comparable. At 1 year, there was no difference in TLF (5.4% in the PD vs. 2.6% in the non-PD group, p¼0.13); all individual components of TLR, death, and MI were also similar. There were no significant differences in MACE and def/probable stent thrombosis between the two groups. Conclusions: These results reflect very similar final angiographic and clinical results achieved with or without post-dilatation in the treatment of low to moderately complex lesions.
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Long term clinical data of the BIOSOLVE-I study with the paclitaxel-eluting absorbable magnesium scaffold (DREAMS) and multi-modality imaging analysis Background: In order to assess the long term safety, clinical performance and the bioabsorption process of the paclitaxel-eluting absorbable magnesium Scaffold (DREAMS) 3-year clinical data and multi-modality imaging outcomes are reported. Methods: Forty-six subjects were enrolled in the first-in-man BIOSOLVE-I study in two different cohorts with clinical follow-up at 1, 6, 12, 24 and 36 months; angiographic and IVUS follow-up for cohort 1 at 6-month and for cohort 2 at 12-month. A subgroup of patients underwent OCT and vasomotion testing. The primary endpoint is Target Lesion Failure (TLF) at 6-month for cohort 1 and at 12-month for cohort 2. For some patients also 18-month and 24-month imaging data are available. Results: TLF rate at 36-month was 6.8% including 2 TLRs and 1 peri-procedural MI occurring at the 12-month follow-up angiography; no events emerged from 12-to 36-month. No cardiac death or scaffold thrombosis was observed. Vasoconstriction after acetylcholine at 6-month (delta¼-10.04%; p¼0.0008 versus baseline) followed by vasodilatation after nitroglycerine (delta¼8.69%; p< 0.0001 versus baseline) demonstrates the uncaging aspect of the absorption process with no further change at the 12-month follow-up. Six-month virtual histology (VH) data showed a significant decrease in the dense calcium by 39.5% (p¼0.0015) remaining stable from 6-to 12-month follow-up. This decrease is interpreted as a surrogate assessment for the bioabsorption process of the scaffold material. Echogenicity data using the decrease in intensity of the ultrasound signal to quantify the change in strut structure demonstrate a continuous decrease in % hyperechogenicity over the follow-up period, with the most pronounced changes within the first 6 months (22 to 16% p< 0.001).
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM-7:00 PM www.jacctctabstracts2014.com B182 JACC Vol 64/11/Suppl B j September 13-17, 2014 j TCT Abstracts/Stents -Drug-eluting: Bioresorbable Scaffolds
Conclusions: DREAMS shows excellent safety and efficacy data with no death and no scaffold thrombosis up to 3 years in the BIOSOLVE-I trial. Multi-modality imaging documented the absorption process and the uncaging aspect of this device already at 6 months.
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Expanding Background: Bioresorbable stents have not been evaluated in a wide range of clinical settings including ACS, STEMI, in-stent restenosis, SVG, and CTO. As of April 1st 2013, ABSORB BVS (BVS) became our default drug eluting device for patients at our institution. The aim of this study is to evaluate the safety and efficacy of this new technology in a real-world setting. Methods: Detailed patient characteristics and peri-procedural data are collected for both patients receiving and not receiving a BVS and systematically entered in a registry. In-hospital outcomes include MACE and bleeding complications and are independently assessed by dedicated personnel. Results: We will report on our first year experience with BVS. Results are compared to those in a group of patients treated concomitantly with other stent types. As of March 31st 2013, 504 BVS have been implanted in 339 patients. Unadjusted MACE (death, MI, Urgent PCI) rates were 2.0%, 2.4%, and 3.9% in patients treated with BVS, DES and BMS, respectively. Conclusions: Conclusions will be supported by the presented data and will reflect our main findings. Preliminary results suggest comparable clinical outcomes with BVS and DES in patients without contra-indication to drug-eluting devices. Results: The number of complex lesions (ACC/AHA lesion classification type B2 and C) between BVS and DES group (84.7% vs. 90.6%, p¼0.01) was similar. Pre and post-balloon dilatation were performed more frequently in the BVS group compared to the DES group (97.1% vs. 79.4%, p< 0.01; 99.2% vs. 79.4%, p< 0.01, respectively). Maximum post dilatation balloon size was larger and maximum inflation pressure was higher in the BVS compared to the DES group (3.2AE0.4 mm vs. 3.0AE0.1 mm, p¼0.01; 21.1AE5.1 atm vs. 19.2AE5.0 atm, p< 0.01, respectively), despite similar quantitative coronary angiogram (QCA) results. Procedure time, amount of contrast and fluoroscopy time in BVS group were increased significantly compared to those in the DES group (Table) . In multivariable analysis, after adjustment for SYNTAX score, chronic total occlusion and lesion length by QCA, BVS use was identified as an independent predictor of long procedure time (> 120 min.) (odds ratio: 4.9, 95% confidence interval: 2.67-9.36, p< 0.001).
Conclusions: Treating complex lesions with BVS requires longer procedure/ fluoroscopy times and larger volumes of contrast as compared to DES implantation to achieve similar procedural success rates and results. Improvements in scaffold design may reduce the need for meticulous lesion predilatation with dedicated devices and increase the spectrum of lesions amenable to treatment with BVS. 
